Skip to content

Smoking Cessation Study - CESTO II

A Phase II Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy

Examination of a novel pharmacotherapy for smoking cessation.

We are recruiting smokers aged 18 to 70 who are seriously interested in attempting to quitting smoking. Eligible smokers will be randomised (assigned by chance) to receive either the novel study drug being tested, or a placebo. The duration of your participation will be approximately 13 months.

Please refer to the Participant Information Sheet for further details.